PPARG and Hepatic fibrosis: Despite early studies showing that the full PPARγ thiazolidinedione agonists could inhibit HSC activation in vitro [7,16,17] and prevent hepatic fibrosis in some rodent models [7,8,9,18,19], studies of their effects in the more clinically relevant models of established hepatic fibrosis have yielded conflicting results.